MASI trades 2.2% above Wall Street's consensus target of $176.00.
Last 12 months price action with 12-month analyst target path
The base valuation assumes MASI achieves its forward estimates and maintains a stable P/E multiple of 32.7x. This scenario reflects the blended consensus of 23 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of September 24, 2026, Masimo Corporation (MASI) has a Wall Street consensus price target of $176.00, based on estimates from 23 covering analysts. With the stock currently trading at $179.95, this represents a potential downside of -2.2%. The company has a market capitalization of $9.42B.
Analyst price targets range from a low of $136.00 to a high of $200.00, representing a 36% spread in expectations. The median target of $180.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 14 analysts rating the stock as a Buy or Strong Buy,9 rating it Hold, and 0 rating it Sell or Strong Sell. The positive sentiment balance indicates moderate optimism about the stock prospects.
From a valuation perspective, MASI trades at a trailing P/E of -64.3x and forward P/E of 32.7x. Analysts expect EPS to grow +279.0% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $25.01, with bear and bull scenarios of $15.76 and $32.96 respectively. Model confidence stands at 44/100, suggesting limited visibility into future performance.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PODDInsulet Corp. | $9.5B | $136.49 | $185.18 | +35.7% | Buy | 21.0x | 50 |
 HOLXHologic, Inc. | $17.0B | $76.01 | $78.69 | +3.5% | Hold | 17.2x | 42 |
 NVCRNovocure Ltd | $1.9B | $16.25 | $26.00 | +60.0% | Buy | — | 15 |
 ITGRInteger Holdings Corporation | $4.3B | $126.32 | $118.25 | -6.4% | Buy | 20.5x | 16 |
 ICUIICU Medical, Inc. | $4.1B | $163.32 | $186.40 | +14.1% | Buy | 18.7x | 12 |
 NTRANatera, Inc. | $56.0B | $390.79 | $335.07 | -14.3% | Buy | — | 28 |
 INVAInnoviva, Inc. | $1.5B | $20.24 | $38.00 | +87.7% | Buy | 8.2x | 10 |
 NOVTNovanta Inc. | $5.1B | $144.43 | $194.00 | +34.3% | Buy | 39.1x | 3 |
 MMSIMerit Medical Systems, Inc. | $5.2B | $87.07 | $101.88 | +17.0% | Buy | 20.2x | 15 |
 HAYWHayward Holdings, Inc. | $2.8B | $12.75 | $15.75 | +23.5% | Hold | 14.7x | 10 |
Quick answers to the most common questions about buying MASI stock.
Wall Street's consensus price target for MASI is $176, -2.2% from its current price of $179.95. The below-market target from 23 analysts suggests limited near-term appreciation.
MASI has a consensus rating of "Buy" based on 23 Wall Street analysts. The rating breakdown is predominantly bullish, with 14 Buy/Strong Buy ratings. The consensus 12-month price target of $176 implies -2.2% downside from current levels.
MASI trades at a forward P/E of 32.7277x, representing a moderate valuation. With analysts targeting $176 (-2.2% implied move), the stock appears close to fair value.
The most bullish Wall Street analyst has a price target of $200 for MASI, while the most conservative target is $136. The consensus of $176 represents the median expectation. Our quantitative valuation model projects a bull case target of $33 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
MASI is well covered by analysts, with 23 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 14 have Buy ratings, 9 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month MASI stock forecast based on 23 Wall Street analysts shows a consensus price target of $176, with estimates ranging from $136 (bear case) to $200 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $25, with bear/bull scenarios of $16/$33.
Our quantitative valuation model calculates MASI's fair value at $25 (base case), with a bear case of $16 and bull case of $33. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 44/100.
MASI trades at a forward P/E ratio of 32.7x based on next-twelve-months earnings estimates. The higher forward P/E suggests near-term earnings pressure. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Analysts are cautious on MASI, with 0 Sell ratings and a price target of $176 (-2.2% from current price). The "Buy" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
MASI analyst price targets range from $136 to $200, a 36% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $176 consensus represents the middle ground. Our model's $16-$33 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.